Extending survival with chemotherapy in metastatic breast cancer.

By J. O’Shaughnessy. The Oncologist, 2005

662 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. (2007, background): “Bevacizumab has shown efficacy when combined with capecitabine and taxanes in advanced breast cancer [38], and the”
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA (2016, background): “Although progress has been made in treating early-stage breast cancer, there is no effective strategy to prevent or treat metastasis, which is the major cause of breast cancer-related mortality (3).”
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study (2017, background): “Despite advances in the treatment of breast cancer and an encouraging 5-year overall survival rate of approximately 90% in the United States, up to 30% of patients with an early-stage diagnosis eventually progress to incurable metastatic disease, and 6% of patients have metastatic disease at diagnos”